MIRA Pharmaceuticals (MIRA) Competitors $1.40 +0.02 (+1.45%) Closing price 04:00 PM EasternExtended Trading$1.40 +0.00 (+0.29%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MIRA vs. SRZN, ONCY, IOBT, EQ, ANEB, VTGN, TCRX, PLRX, ADAG, and ANROShould you be buying MIRA Pharmaceuticals stock or one of its competitors? The main competitors of MIRA Pharmaceuticals include Surrozen (SRZN), Oncolytics Biotech (ONCY), IO Biotech (IOBT), Equillium (EQ), Anebulo Pharmaceuticals (ANEB), VistaGen Therapeutics (VTGN), TScan Therapeutics (TCRX), Pliant Therapeutics (PLRX), Adagene (ADAG), and Alto Neuroscience (ANRO). These companies are all part of the "pharmaceutical products" industry. MIRA Pharmaceuticals vs. Its Competitors Surrozen Oncolytics Biotech IO Biotech Equillium Anebulo Pharmaceuticals VistaGen Therapeutics TScan Therapeutics Pliant Therapeutics Adagene Alto Neuroscience MIRA Pharmaceuticals (NASDAQ:MIRA) and Surrozen (NASDAQ:SRZN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, media sentiment, dividends, risk, institutional ownership and earnings. Which has more volatility & risk, MIRA or SRZN? MIRA Pharmaceuticals has a beta of 1.75, meaning that its stock price is 75% more volatile than the S&P 500. Comparatively, Surrozen has a beta of 0.62, meaning that its stock price is 38% less volatile than the S&P 500. Is MIRA or SRZN more profitable? MIRA Pharmaceuticals has a net margin of 0.00% compared to Surrozen's net margin of -274.42%. MIRA Pharmaceuticals' return on equity of -406.70% beat Surrozen's return on equity.Company Net Margins Return on Equity Return on Assets MIRA PharmaceuticalsN/A -406.70% -328.44% Surrozen -274.42%-545.43%-64.40% Does the media refer more to MIRA or SRZN? In the previous week, Surrozen had 7 more articles in the media than MIRA Pharmaceuticals. MarketBeat recorded 8 mentions for Surrozen and 1 mentions for MIRA Pharmaceuticals. Surrozen's average media sentiment score of 1.00 beat MIRA Pharmaceuticals' score of 1.00 indicating that Surrozen is being referred to more favorably in the news media. Company Overall Sentiment MIRA Pharmaceuticals Positive Surrozen Positive Do institutionals & insiders believe in MIRA or SRZN? 35.2% of MIRA Pharmaceuticals shares are held by institutional investors. Comparatively, 66.6% of Surrozen shares are held by institutional investors. 6.7% of MIRA Pharmaceuticals shares are held by insiders. Comparatively, 45.2% of Surrozen shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has better earnings & valuation, MIRA or SRZN? MIRA Pharmaceuticals has higher earnings, but lower revenue than Surrozen. MIRA Pharmaceuticals is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMIRA PharmaceuticalsN/AN/A-$7.85M-$0.49-2.86Surrozen$10.65M9.82-$63.56M-$14.42-0.85 Do analysts rate MIRA or SRZN? MIRA Pharmaceuticals presently has a consensus price target of $17.00, indicating a potential upside of 1,114.29%. Surrozen has a consensus price target of $38.50, indicating a potential upside of 215.57%. Given MIRA Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe MIRA Pharmaceuticals is more favorable than Surrozen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MIRA Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Surrozen 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryMIRA Pharmaceuticals and Surrozen tied by winning 8 of the 16 factors compared between the two stocks. Get MIRA Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MIRA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MIRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MIRA vs. The Competition Export to ExcelMetricMIRA PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$26.32M$3.12B$5.77B$9.91BDividend YieldN/A2.29%6.71%4.52%P/E Ratio-2.8620.9775.5426.08Price / SalesN/A290.09482.3489.45Price / CashN/A44.9736.9659.01Price / Book10.779.8611.446.09Net Income-$7.85M-$53.47M$3.28B$266.14M7 Day Performance2.19%2.89%0.84%0.28%1 Month Performance-8.50%8.62%7.15%4.14%1 Year Performance-11.39%13.69%59.66%23.93% MIRA Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MIRAMIRA Pharmaceuticals2.9108 of 5 stars$1.40+1.4%$17.00+1,114.3%-18.8%$26.32MN/A-2.862Short Interest ↓SRZNSurrozen2.7347 of 5 stars$12.19+4.4%$38.50+215.8%+21.6%$104.43M$10.65M-0.8580News CoveragePositive NewsGap UpHigh Trading VolumeONCYOncolytics Biotech1.858 of 5 stars$1.04-2.8%$5.00+380.8%+6.9%$104.38MN/A-3.8530IOBTIO Biotech2.2456 of 5 stars$1.58flat$8.67+448.5%+84.3%$104.09MN/A-1.0030Short Interest ↑EQEquillium0.4754 of 5 stars$1.74-4.4%$1.00-42.5%+76.6%$103.54M$41.10M-3.1140News CoverageShort Interest ↑ANEBAnebulo Pharmaceuticals2.028 of 5 stars$2.50-0.8%$5.50+120.0%+27.1%$102.71MN/A-9.624VTGNVistaGen Therapeutics0.9915 of 5 stars$3.34+3.4%N/A+11.0%$102.47M$490K-1.8840TCRXTScan Therapeutics2.6727 of 5 stars$1.80-1.1%$7.80+333.3%-66.2%$102.15M$2.82M-1.65100News CoveragePLRXPliant Therapeutics4.112 of 5 stars$1.64+1.2%$8.19+399.2%-87.3%$100.68M$1.58M-0.4890News CoveragePositive NewsADAGAdagene3.3278 of 5 stars$2.13-4.1%$7.00+228.6%-25.2%$100.39M$100K0.00260Short Interest ↓Gap DownANROAlto Neuroscience2.8538 of 5 stars$3.71-2.8%$8.50+129.4%-73.7%$99.64MN/A-1.55N/A Related Companies and Tools Related Companies Surrozen Competitors Oncolytics Biotech Competitors IO Biotech Competitors Equillium Competitors Anebulo Pharmaceuticals Competitors VistaGen Therapeutics Competitors TScan Therapeutics Competitors Pliant Therapeutics Competitors Adagene Competitors Alto Neuroscience Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MIRA) was last updated on 9/5/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredOne tiny company just cracked Google’s $19B problemFor decades, this “AI metal” was trapped in labs, too slow and expensive to ever reach mass production. The...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MIRA Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MIRA Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MIRA Stock Alerts